The Competition Commission of South Africa has initiated another important complaint involving TB drugs

Aug 15, 2024

1 min read

The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to investigate a complaint against Otsuka. The HJI has reported that the company is alleged to be engaging in exclusionary practices for the drug Delamanid. A hearing for the complaint has not been scheduled with the tribunal at this time.

Recent Posts

See All

Long a dream, its now real: a fast and accurate TB test that doesn't need phlegm.

Phlegm remains the most common test for determining if an individual has TB - a practice that has not changed much since the 1800s and poses many challenges for both patients and health care professio

New free eLearning Programme with The Union: 'Drug-Resistant Tuberculosis: From Clinical to Programmatic'

The International Union Against Tuberculosis and Lung Disease (The Union) is offering a free and accessible course created for clinicians and program managers who are working or planning to work with

Trials to watch: Phase III TB vaccines and MDR-TB treatments

After years without much advancement in new TB drug trials, a vaccine and two treatments are progressing through late-stage studies. As researchers predict the number of TB cases in the 16 major marke

Comments